Bexion Pharmaceuticals, Inc., a US-based mid-stage biopharmaceutical company, announced on Thursday that it has named Joyce LaViscount as its new chief financial officer (CFO).

LaViscount has more than 30 years of experience within start-up organisations to Fortune 100 companies with diverse leadership roles across finance, accounting, and operations. She has held the position of chief financial officer at Panavance Therapeutics, CFO and COO for Helius Medical Technologies. She has served in roles of increasing responsibility at Pfizer/Pharmacia, Bristol-Myers Squibb and Endo Pharmaceuticals.

Scott Shively, Bexion's chief executive officer and president, said, 'Joyce has a proven track record of results-driven leadership, strategic thinking and financial acumen, and has proven experience in both private and public company settings. We look forward to her joining our team and contributing to Bexion's continued progression as a company as we progress our lead product BXQ-350 and continue to build our capital structure.'